Cowen Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Stifel Starts Akcea Therapeutics, Inc. (AKCA) at Buy
August 8, 2017 5:21 AM EDTStifel initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Buy rating and a price target of $19.00.
Analyst Stephen Willey says that while there may be more stringent patient monitoring requirements expected to accompany Volanesorsen commercialization, he believes the significant... More
BMO Capital Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:11 AM EDTBMO Capital initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $25.00.
Analyst Do Kim expects Volanesorsen approval for familial chylomicronemia syndrome (FCS) sometime in H2 2018 and estimates WW peak sales could be $850 million assuming... More
Wells Fargo Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:09 AM EDTWells Fargo initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $27.00.
Analyst Jim Birchenough sees a blockbuster opportunity for lead antisense oligonucleotide therapeutic Volanesoren in patients with familial chylomicronemia syndrome (FCS). The analyst believes the... More
